Evaluation of the effect of miltefosine on Trichomonas vaginalis
- 409 Downloads
Trichomonas vaginalis causes trichomoniasis in humans, a sexually transmitted disease commonly treated with metronidazole (MTZ). MTZ is known to cause undesirable side effects, and MTZ-resistant parasites have been reported. Thus, the development of an alternative treatment is desirable. Miltefosine (MLT) is an alkylphosphocholine synthetic lipid analogue that displays antiparasitic activity against Leishmania, Trypanosoma cruzi, Entamoeba histolytica, Acanthamoeba spp., Giardia lamblia, T. vaginalis and some fungi. Moreover, it has been used for oral treatment of visceral leishmaniosis in several countries. Here, we analysed the MLT-induced antiproliferative effect on T. vaginalis as well its effect on the fine structure and viability of the parasite. We observed a dose-dependent effect with an IC50 of 14.5 and 20 μM after 24 and 48 h, respectively. Furthermore, reversibility assays demonstrated that new incubations were necessary in order to maintain the antiproliferative effect. Ultrastructural analyses demonstrated that MLT induced several alterations, including the appearance of wrinkled and rounded cells, membrane blebbing, intense vacuolization and nuclear condensation, all indicative of cell death by apoptosis. In addition, the quantitative analyses of the viability assays using combined markers of live and dead cells demonstrated that treatment with the IC50 concentration of MLT significantly reduced the number of viable parasites compared with untreated cells. Taken together, these observations suggest that MLT is a promising compound for the treatment of trichomoniasis.
KeywordsVisceral Leishmaniasis Parasite Growth Perifosine Entamoeba Histolytica Miltefosine
This work was supported by Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Programa de Núcleos de Excelência (PRONEX), Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ) and Associação Universitária Santa Úrsula (AUSU).
The experiments comply with the current laws of this country.
Conflict of interest
The authors declare that they have no conflict of interest.
- Cotch MF, Pastorek JG, Nugent RP, Hillier SL, Gibbs RS, Martin DH, Eschenbach DA, Edelman R, Carey JC, Regan JA, Krohn MA, Klebanoff MA, Rao AV, Rhoads GG (1997) Trichomonas vaginalis associated with low birth weight and preterm delivery. The vaginal infections and prematurity study group. Sex Transm Dis 24:353–360PubMedCrossRefGoogle Scholar
- Kulda J, Vojtĕchovská M, Tachezy J, Demes P, Kunzová E (1982) Metronidazole resistance of Trichomonas vaginalis as a cause of treatment failure in trichomoniasis—a case report. Br J Ven Dis 58:394–399Google Scholar
- Lira R, Contreras LM, Rita RM, Urbina JA (2001) Mechanism of action of anti-proliferative lysophospholipid analogues against the protozoan parasite Trypanosoma cruzi: potentiation of in vitro activity by the sterol biosynthesis inhibitor ketoconazole. J Antimicrob Chemother 47:537–546PubMedCrossRefGoogle Scholar
- Lossick JG (1990) Treatment of sexually transmitted vaginosis/vaginitis. Rev Infect Dis Suppl 6:S665–681Google Scholar
- Martin MB, Grimley JS, Lewis JC, Heath HT, Bailey BN, Kendrick H, Yardley V, Caldera A, Lira R, Urbina JA, Moreno SN, Docampo R, Croft SL, Oldfield E (2001) Bisphosphonates inhibit the growth of Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, and Plasmodium falciparum: a potential route to chemotherapy. J Med Chem 44:909–916PubMedCrossRefGoogle Scholar
- Robinson SC (1962) Trichomonal vaginitis resistant to metranidazole. Can Med As J 86:665–666Google Scholar
- Saraiva VB, Gibaldi D, Previato JO, Mendonça-Previato L, Bozza MT, Freire-De-Lima CG, Heise N (2002) Proinflammatory and cytotoxic effects of hexadecylphosphocholine (miltefosine) against drug-resistant strains of Trypanosoma cruzi. Antimicrob Agents Chemother 46:3472–3477PubMedCentralPubMedCrossRefGoogle Scholar
- Serrano-Martín X, Payares G, De Lucca M, Martinez JC, Mendoza-León A, Benaim G (2009) Amiodarone and miltefosine act synergistically against Leishmania mexicana and can induce parasitological cure in a murine model of cutaneous leishmaniasis. Antimicrob Agents Chemother 53:5108–5113PubMedCentralPubMedCrossRefGoogle Scholar
- Soto J, Soto P (2006) Current situation and future of anti-leishmanial therapy in Colombia. Biomedica 1:194–206Google Scholar
- Sutcliffe S, Giovannucci E, Alderete JF, Chang TH, Gaydos CA, Zenilman JM, De Marzo AM, Willett WC, Platz EA (2006) Plasma antibodies against Trichomonas vaginalis and subsequent risk of prostate cancer. Cancer Epidemio Biom Prev 15:939–945Google Scholar
- World Health Organization (WHO) (2001) Global prevalence and incidence of selected curable sexually transmitted infections. In Global Program on AIDS, Geneva, Switzerland: World Health Organization 2–27Google Scholar